What the trials showed.
The STEP 1 extension trial followed patients for a year after semaglutide was discontinued. The results were sobering: participants regained roughly two-thirds of the weight they had lost within 12 months of stopping. Appetite returned. The metabolic advantages faded. For many, it was as if the medication had never been taken.
Similar patterns have been observed with tirzepatide. In the SURMOUNT-4 trial, participants who switched from tirzepatide to placebo regained approximately 14 percentage points of body weight during the subsequent randomized period, while those continuing tirzepatide maintained or extended their weight loss.
These are averages. But the direction is consistent. For most people, GLP-1 medications don't create permanent metabolic change. They suppress appetite and alter energy regulation while you're taking them. When they stop, the biological drive to return to a higher weight reasserts itself.
This is not a character flaw. It's physiology. Obesity involves persistent changes in appetite-regulating hormones, set-point mechanisms, and metabolic adaptation that don't reset simply because you lost weight. The medication was counteracting those forces. When it's withdrawn, the forces are still there.
Why I'm telling you this upfront.
I'm not saying this to discourage anyone from starting GLP-1 therapy. I'm saying it because a responsible physician discusses the full trajectory of treatment before day one — not after you've lost 40 pounds and want to come off.
The pharmaceutical reality is that many patients will need to stay on some dose of a GLP-1 long-term, just as a patient with hypertension often stays on an antihypertensive long-term. That's not a failure of the treatment. It's the nature of managing a chronic metabolic condition.
But "stay on it forever" isn't a complete plan. And for some patients, it's not necessary — if the right foundation is built while they're on the medication.
Factors that may influence your outcome.
Several factors may influence outcomes after medication discontinuation, though evidence has not established that any specific strategy reliably prevents pharmacologic-withdrawal weight regain. That said, building the strongest possible foundation during treatment is sound clinical practice.
Muscle mass
Patients who lost significant lean mass during treatment are at higher risk of regain. Their resting metabolic rate is lower. Their capacity for physical activity is reduced. Their body is metabolically less efficient than it was before treatment, even though it's lighter. This is why I'm so aggressive about muscle preservation during active weight loss.
Metabolic health markers
If a patient's insulin sensitivity, lipid profile, and inflammatory markers have genuinely improved during treatment — not just because of weight loss, but because of concurrent lifestyle changes — they have a better foundation for maintaining weight.
Behavioral adaptation
GLP-1 medications give patients a window. Appetite is quieter. Food noise is reduced. That window is an opportunity to build eating patterns and habits that can persist after the medication is reduced or stopped. Patients who use that window — who restructure their relationship with food while the medication makes it easier — tend to do better than patients who simply eat less without changing what or how they eat.
Hormonal status
This is something most GLP-1 prescribers don't think about. Significant weight loss can unmask or worsen hormonal issues — thyroid dysfunction, testosterone deficiency — that themselves contribute to weight regain. If nobody checked, nobody knows.
How I approach this: By the time a patient reaches their goal weight, they should have a clear maintenance plan. For some, that means a lower maintenance dose of the GLP-1 — not the maximum therapeutic dose, but enough to sustain the new set point. For others, it means transitioning off the medication with structured monitoring: monthly weigh-ins, quarterly labs, protein and training targets, and a clear agreement that we re-start medication early if meaningful regain begins. I don't wait for someone to gain back 30 pounds before intervening. At Wellesley Medical, one approach is to set individualized thresholds for each patient and act before the trajectory becomes unmanageable.
The maintenance question.
There's an emerging clinical consensus that many patients will benefit from long-term, lower-dose GLP-1 therapy as a maintenance strategy. The STEP 4 trial randomized patients who had already responded to semaglutide to either continue treatment or switch to placebo. Those who continued maintained their weight loss; those who switched regained significantly. The STEP 1 extension data showed a similar pattern over a longer follow-up.
I don't see this as a problem. We don't ask patients with high blood pressure to "come off" their medication to prove they're cured. Metabolic disease often requires ongoing management. The question isn't "can I stop?" — it's "what does my physician recommend for my long-term health?"
For some patients, the answer is ongoing GLP-1 therapy at a maintenance dose. For others, the answer is a structured step-down with monitoring. For a few, it may be appropriate to discontinue entirely with close follow-up.
There isn't one right answer. There's the right answer for you, informed by your response to treatment, your metabolic data, your muscle mass, your hormonal picture, and your personal goals.
The 2026 ADA Standards of Care characterize obesity as a chronic, relapsing condition and discuss long-term pharmacotherapy, individualized maintenance approaches, and close monitoring after discontinuation. That framing aligns with how I approach this in practice.
What I'd want in a physician if this were me.
I'd want someone who told me the truth about regain before I started. I'd want someone who preserved my muscle while I lost weight. I'd want someone who checked my hormones, my metabolic markers, and my body composition — not just my scale weight. I'd want someone who had a maintenance plan ready before I reached my goal weight, not after.
And I'd want someone who didn't treat discontinuation as the default endpoint, but who also didn't treat lifelong maximum-dose therapy as the only option.
That middle ground — informed, individualized, data-driven, and honest — is where good medicine happens. It's where I practice.